RETHINKING Migraine in times of COVID-19 RETHINKING Migraine in times of COVID-19 is a research-driven project offering tangible policy changes to improve the lives of people living with migraine across Europe. It challenges the status quo and refreshes the European policy debate on people living with migraine, recognises the consequences of the burdens [...]
RETHINKING Alzheimer's disease RETHINKING Alzheimer's disease (AD) is a research-driven project offering policy recommendations to make tangible changes with the aim to improve the lives of people living with Alzheimer’s disease across Europe. About Alzheimer's Disease Alzheimer’s disease is a neurodegenerative disease that progresses in stages, beginning with a long silent phase [...]
Identify treatment gaps (or barriers to care) and causing factors along the care pathway and propose solutions to address them. Assess health gains and socio-economic impacts resulting from best practice healthcare interventions, in comparison with current care or no treatment. Converge evidence to policy.
The aim of the RETHINKING Projects is to develop policy priorities around challenges in the management of brain disorders.
The EBC actively supports the adoption of EU guidelines on off-label use of medicines, a policy option presented in the European Commission`s Study on off-label use of medicinal products in the European Union published in February 2017. Off-label use is the practice of using a medicine outside its authorised indication.
The EU-funded AD Detect-Prevent project, which is led by the Danish company Brain+, kicked-off in late 2018 and will continue over the next two years with the aim of developing a digital tool to improve early detection of Alzheimer’s disease.